AZD7121, an orally bioavailable, vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor can be exploited as a senescence inducer in retarding tumor growth [109] and showed limited toxicity in patients with advanced HCC in a phase II clinical trial [110]. The gene discussed is KDR; the disease is neoplasm.